



Okayama University


# DEPARTMENT of CARDIOVASCULAR SURGERY

Welcome to The Department of Cardiovascular Surgery at Okayama University. Our department is dedicated to excellence in patient care. We also perform clinical and basic research on diseases affecting our patients and provide education for the next generation of cardiothoracic surgeons.



## About Our Clinical Department

Our department is specialized in all areas of cardiovascular surgery including congenital and acquired cardiac disease, abdominal and thoracic aneurysms, and peripheral vascular diseases. We are one of the leading hospitals in the world in the field of congenital heart disease. We have contributed to the improvement of clinical results of pediatric cardiac surgery and have achieved top class surgical outcomes. Dr. Sano, the department chief of cardiovascular surgery, invented the Sano shunt, which is a right ventricle–pulmonary artery shunt used in the Norwood procedure as the first palliative operation for patients with hypoplastic left heart syndrome. Following the introduction of the Sano shunt, the clinical results of the modified Norwood procedure in Japan have been dramatically improved. An early survival rate of 97% has been achieved after performing the modified Norwood procedure with the Sano shunt at Okayama University Hospital between 1998 and 2013. We are inviting doctors from other countries to observe or take part in these operations. If you are interested in our clinical activities, please do not hesitate to contact our department.



Dr. Sano

## About Our Research (Department of Regenerative Medicine)



Dr. Oh

Our current main interest for basic research is regenerative therapy using cardiac progenitor cells for patients with congenital heart disease. Dr. Hidemasa Oh is the principal investigator of this research. We conducted a phase I clinical trial (TICAP clinical trial: Transcoronary Infusion of Cardiac Progenitor Cells in Patients with Single Ventricle Physiology) between 2011 and 2013, and found no adverse events. We are now conducting the phase II clinical trial (PERSEUS clinical trial: Cardiac Progenitor Cell Infusion to Treat Univentricular Heart Disease). If you are interested in our research, please feel free to contact our department.

Homepage address : [http://www.shin-iryu.jp/section/index\\_e.html](http://www.shin-iryu.jp/section/index_e.html)

Address (2-5-1, Shikata-cho, Kitaku, Okayama city, Okayama, 700-8558, Japan)

Phone number ( +81-86-235-7359)、 Fax number ( + 81-86-235-7431)

Homepage address : [http://www.hsc.okayama-u.ac.jp/mdps/e\\_index.html](http://www.hsc.okayama-u.ac.jp/mdps/e_index.html)



Department of Cardiovascular Surgery, Okayama University School of Medicine,  
Dentistry, and Pharmaceutical Sciences